HYPE: NAD+ / NMN supplements can slow or reverse ageing
But what does the evidence actually show?
NMN and related supplements can raise NAD-related measurements in human blood. That is not the same as showing that they slow ageing, prevent age-related disease or extend life. Human trials contain some interesting signals, but clinically meaningful benefits are inconsistent. Important 2026 studies reinforce the gap between changing a biomarker and changing health.
Why people believe this
NAD+ — nicotinamide adenine dinucleotide — is a molecule cells use in energy metabolism and other processes, including pathways involved in DNA repair. NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are precursors: substances the body can use to make NAD+. They are related, but they are not identical treatments.
The strongest argument comes from biology and animal experiments. NAD metabolism changes in some ageing tissues, and boosting it can improve selected metabolic or functional outcomes in laboratory models. If a limiting cellular resource can be restored, perhaps some age-related dysfunction could improve.
That is a worthwhile research question. The popular leap is larger: a supplement raises a blood measurement, therefore it makes a person biologically younger. Ageing involves many processes, and a mechanism needs testing against meaningful human outcomes.
What the evidence actually shows
A promising, specific metabolic signal
Yoshino and colleagues studied 25 postmenopausal women with prediabetes and overweight or obesity over ten weeks. NMN improved insulin sensitivity in muscle, but did not clearly improve fasting glucose or liver insulin sensitivity. This is evidence for a particular physiological effect in a particular population, not proof of diabetes prevention or age reversal.
Read the research ↗Metabolic improvements have not been consistent
Chen and colleagues combined eight NMN trials involving 342 adults, generally lasting two to twelve weeks. They found no significant pooled benefit for fasting glucose, fasting insulin, HbA1c, estimated insulin resistance or blood lipids. Most participants were relatively healthy, and the studies were short; the review cannot rule out benefits in every disease or population.
Read the research ↗What about muscle and physical function?
Prokopidis and colleagues reviewed placebo-controlled NMN and NR trials. NMN did not significantly improve the pooled measures of muscle-mass index, grip strength, walking speed or chair-rise performance. This is more relevant to everyday function than a blood NAD increase, although the small and varied trial base leaves uncertainty.
Read the research ↗The important 2026 human evidence
Blood NAD rose; hearing and performance did not
Igarashi and colleagues tested 1,250 mg of NMN daily for 24 weeks in adults aged 65 or older. Blood NAD and related metabolites increased, but the primary hearing outcome and physical-performance measures did not significantly improve. Some nominal changes in other measurements did not remain significant after adjustment for multiple testing. The trial was generally well tolerated, with the authors calling for careful safety monitoring.
Read the research ↗This peer-reviewed accepted paper was released early and may receive further editorial updates. It is especially useful because it tests a sustained intervention and separates biochemical effects from functional outcomes. Twenty-four weeks is still not a longevity study. The reported dose describes the experiment; it is not a recommendation.
Is blood NAD an ageing marker in the first place?
Trętowicz and colleagues used a validated analytical method across seven independent human cohorts. Whole-blood NAD levels were stable with age and across the lifestyle interventions studied, while responding to NR supplementation. This challenges using blood NAD as an ageing marker. It does not show that NAD never changes in specific tissues, or that the molecule is biologically unimportant.
Read the research ↗These findings matter for interpreting commercial “NAD age” measurements. A marker that changes after supplementation is not automatically a validated measure of rejuvenation. Different blood fractions, tissues, sample handling and laboratory methods may produce different answers.
The catch: which treatment, which outcome?
Oral NMN, oral NR, products labelled “NAD+”, and intravenous NAD+ should not be grouped together as one intervention. Their delivery, metabolism and supporting studies differ. Evidence for an oral precursor cannot establish the benefits or safety of an infusion.
A 2026 systematic review of preclinical and clinical evidence found mixed human metabolic, vascular and performance effects. It found no eligible outcomes trials of intravenous or intramuscular NAD+ itself for anti-ageing or wellness indications within its search period. Animal findings and short-term infusion biomarkers should therefore be clearly labelled, rather than presented as a demonstrated wellness benefit.
Some small trials report improvements in selected outcomes. Those signals should be investigated rather than dismissed. But a study measuring many outcomes can produce apparently positive findings by chance. Pre-specified primary outcomes, placebo comparisons, replication and corrections for multiple testing help distinguish a reliable effect from an exploratory lead.
The available studies do not establish that NMN or NAD+ supplements extend human lifespan or reverse ageing. Nor can a short trial establish years of safety, rare adverse effects or safety in pregnancy or complex illness. Products bought outside a trial may also differ from the tested formulation. “No significant benefit detected” is not proof that a benefit is impossible; it is a limit on what can currently be claimed.
How strong is the evidence?
What this means for you
Ask what a product has actually been shown to do: raise a laboratory marker, change a functional test, prevent disease, or extend life? Those claims require different evidence. A “younger” biomarker result is not a substitute for improved health, and an animal result is not a human treatment outcome.
If you are considering supplementation alongside medicines or for a medical condition, discuss it with a clinician or pharmacist. Do not use a longevity claim as a reason to replace established treatment. Physical activity, resistance exercise and an adequate diet address measurable aspects of health without requiring a promise of age reversal.
Raising NAD is demonstrable; reversing human ageing is not established. The science remains interesting, but the strongest marketing claims run ahead of the human outcomes.
Audit update, 4 October 2026: changed the rating from Limited to Weak to assess the human anti-ageing claim separately from the demonstrated biomarker changes; identified the systematic-review authors in the references.
Research & Sources
Yoshino and colleagues (2021)
Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women.
Chen and colleagues (2024)
Effects of NMN on glucose and lipid metabolism in adults: systematic review and meta-analysis of randomised controlled trials.
Prokopidis and colleagues (2025)
The Effect of Nicotinamide Mononucleotide and Riboside on Skeletal Muscle Mass and Function: A Systematic Review and Meta-Analysis.
Igarashi and colleagues (2026)
Sustained NAD+ augmentation by high-dose NMN supplementation in older adults: a 24-week randomised, double-blind, placebo-controlled trial.
Trętowicz and colleagues (2026)
Human whole-blood NAD+ levels do not vary with age or lifestyle interventions.
Gallagher and Emmanuel (2026)
NAD+ supplementation for anti-aging and wellness: a PRISMA-guided systematic review of preclinical and clinical evidence.
Evidence reviewed: October 2026. Searches included 2025 and 2026 research as well as relevant older studies. This is an editorial investigation, not an exhaustive systematic review.
Evidence vs Hype explains scientific research for educational purposes and does not provide individual medical diagnosis or treatment.
For related longevity claims, compare our investigations of biological-age tests and claims of age reversal and hydrogen water for recovery and ageing. Each asks whether the measured outcome supports the promised benefit.